MeVis Medical Solutions AG
ISIN: DE000A0LBFE4
WKN: A0LBFE
29 January 2024 07:00PM

EQS-News: MeVis publishes figures for financial year 2022/2023 and forecast for 2023/2024

MeVis Medical Solutions AG · ISIN: DE000A0LBFE4 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1825455

EQS-News: MeVis Medical Solutions AG / Key word(s): Annual Results
MeVis publishes figures for financial year 2022/2023 and forecast for 2023/2024

29.01.2024 / 19:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


  • Turnover down by € 1.5 million to € 17.3 million
  • EBIT of € 3.9 million, 23% margin
  • Earnings after taxes down by € 2.9 million to € 4.9 million
  • Forecast for the 2023/2024 financial year
    • Slight increase in sales from € 18.0 million to € 18.5 million
    • EBIT stable at € 4.5 million to € 5.0 million

 

Bremen, January 29, 2024 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, announces its results for the fiscal year 2022/2023, with reporting period October 1, 2022 to September 30, 2023.

Revenue in the past financial year 2022/2023 amounted to € 17.3 million (compared to € 18.8 million in the financial year 2021/2022). Of the revenue, 26 % (previous year: 28 %) is attributable to the sale of licenses, 36 % (previous year: 32 %) to maintenance revenue and 38 % (previous year: 38 %) to other revenue, which includes services for and recharges to affiliated companies and the parent company.

The decline in sales compared to the previous year is mainly due to the decline in the license business, but also to the postponement of a development project, which we now expect to start in 2024. Other revenue, especially development services, fell slightly, while maintenance revenue continued to develop very positively.

The results are still satisfactory in view of the development of sales. EBIT (earnings before interest and taxes) of € 3.9 million was generated in 2022/2023, compared to € 7.9 million in 2021/2022. The EBIT margin fell accordingly to 23 % compared to the previous year's figure of 42 %.

As a result of the fiscal unity, only low income taxes of € 0.1 million were incurred in the past financial year, identical to the previous year.

This results in earnings after taxes of € 4.9 million (28% margin) for the 2022/2023 financial year, compared to € 7.8 million (41% margin) in 2021/2022. The profit of € 4,920 thousand will be transferred to Varex Imaging Deutschland AG on the basis of the control and profit transfer agreement.

For the 2023/2024 financial year, sales are now expected to increase slightly year-on-year to between € 18.0 million and € 18.5 million. In addition to the slight increase in sales with the customer Hologic, sales in the lung and liver area are also expected to increase slightly. We expect a slight decline in the area of development services. For earnings before interest and taxes (EBIT), we expect stability in the range of € 4.5 million to € 5.0 million. The forecast slight growth in sales and the simultaneous increase in personnel costs and other operating expenses are key drivers for the EBIT outlook.

The half-year financial report for the 2023/2024 financial year will be published on May 27, 2024.

 


Contact:
Kirchhoff, Marcus / CEO


29.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1825455

 
End of News EQS News Service

1825455  29.01.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1825455&application_name=news&site_id=boersengefluester_html

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 16,76 18,07 17,13 16,21 18,76 17,34 18,30
EBITDA1,2 7,60 8,25 5,97 4,77 7,99 3,99 4,91
EBITDA-Margin3 45,35 45,66 34,85 29,43 42,59 23,01 26,83
EBIT1,4 6,69 8,00 5,81 4,64 7,90 3,89 4,80
EBIT-Margin5 39,92 44,27 33,92 28,62 42,11 22,43 26,23
Net Profit (Loss)1 7,17 8,07 5,70 4,55 7,79 4,92 5,70
Net-Margin6 42,78 44,66 33,28 28,07 41,53 28,37 31,15
Cashflow1,7 5,52 6,55 2,89 9,13 4,86 5,85 0,00
Earnings per share8 3,94 4,43 3,13 2,50 4,28 2,70 3,15
Dividend per share8 0,95 0,95 0,95 0,95 0,95 0,95 0,95
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Deloitte

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
MeVis Med. Solutions
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A0LBFE DE000A0LBFE4 AG 44,41 Mio € 16.11.2007 Halten 9F5C4V35+HX
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
10,17 10,24 0,99 7,43 2,49 7,59 2,56
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,95 0,95 0,95 3,89%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
19.03.2024 - 27.05.2025 - 30.01.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-0,81%
24,40 €
ATH 53,89 €
+0,25% -2,36% -3,17% -3,17% -55,64%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL